Investor Relations

Corporate Profile

We are a biopharmaceutical company focused on harnessing powerful biology underlying major diseases to develop transformative therapeutics for patients.

We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines.

We aspire to operate one of our industry’s most productive research and development engines and have built a robust pipeline of drug candidates – several of which are in clinical development – to address a spectrum of large, unmet medical needs. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. However, we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News and Events

Press Releases

  • 07/22/21

    NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

    Read more
  • 07/07/21

    NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors

    Read more
  • 07/01/21

    NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases

    Read more

Events

  • More events are coming soon.

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Top